Together Against Child Mortality: Novartis and Save the Children Launch Health Project in the Slums of Nairobi
BASEL, SWITZERLAND, August 2, 2021 /3BL Media/ - Novartis and children’s rights organization Save the Children are launching their first common health project tackling child mortality in Kenya's Kibera and Mathare slums. This is a first step in their collaboration with the objective of providing affordable and effective healthcare to the most deprived children in Kenya. The project will help improve the case management of common childhood diseases like pneumonia through trainings of community health volunteers in Nairobi.
Dr. Lutz Hegemann, Group Head of Corporate Affairs and Global Health at Novartis says: “Novartis is committed to delivering sustainable healthcare solutions to help transform the lives and health of underserved populations. We are excited to join forces with Save the Children to help reduce the number of children under the age of 5 dying from preventable and treatable diseases.”
Adrian Förster, CEO of Save the Children Switzerland says: "This project is the start of a powerful partnership that will improve the living conditions of the most deprived children. We see that high-density urban centres are very challenging for children and their ability to grow up healthy. We are very happy to join our expertise and our capacity with Novartis to improve the access to medical treatment and the health of children in this particular context."
The planned health project is located in Kenya's urban slums including Kibera and Mathare in Nairobi County and aims to improve access to medical support. Local community and health volunteers are trained to diagnose and treat common diseases in children. Malaria, pneumonia, diarrhea and malnutrition cause the majority of preventable deaths among children under the age of five. Through the project, Novartis and Save the Children aim at tackling under five mortality and improving support for the most deprived children in urban, high-density centres.
Mathare and Kibera are home to thousands of the urban poor, living in deprived sanitary conditions and inadequate shelter. Inhabitants of these slums lack access to basic water and sanitation, paucity of health care facilities and vulnerability in getting infectious diseases. This holistic program, targeting the main causes of morbidity and mortality amongst children, will go a long way in reducing the incidence of communicable diseases. The project also seeks to improve the social economic conditions of the communities, through timely response, accessing care and economic empowerment through a community savings scheme. Health education, prevention of disease and early treatment are some of the key interventions that will bring change in the community. This program supplements what other organizations are doing to improve the lives of the urban poor.
This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact email@example.com
# # #
Novartis Media Relations
Novartis External Communications
+41 79 723 3681 (mobile)
Novartis Corporate Affairs & Global Health Communications
+41 79 334 4325 (mobile)